Pruritus Therapeutics Market By Drug type (Corticosteroids, Antihistamines, Local Anesthetics, Immunosuppressant, Others), By Disease Type (Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Others), By Distribution Channel (Hospital Pharmacies, Drug stores & Retail Pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global pruritus therapeutics market was valued at $7,849.4 million in 2021, and is projected to reach $11,186.15 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.
Pruritus therapeutics are medications used in treatment of pruritus. Pruritus causes itching of skin, owing to number of issues such as dry skin, allergy, and other ailments. It is a skin ailment that, if ignored, can cause persistent pain and have a negative influence on quality of life. For instance, anxiety, attention-deficit, or hyperactivity disorder and sleep disturbance can all be brought on by pruritus. In addition, it might result in systemic and mental conditions, if left untreated. A more significant underlying cause is typically indicated when pruritus persists for a longer time. A heightened inflammatory response to a multitude of possible irritants, such as dust, environmental pollutants, animals, and certain food can cause eczema, also known as atopic dermatitis. Atopic dermatitis commonly manifests as rashes, scaly areas, and itching on face, arms, or legs. Allergic contact dermatitis happens when people come into touch with substances that might harm their skin, such as chemicals. Typical products that cause contact dermatitis include watches, soaps, garments, and jewelry produced with potentially irritating substances.
Medical professionals have utilized corticosteroids as a topical dosage form for treating pruritus for many years. The first-line pharmacological therapy for pruritus and associated skin itch diseases such AD, allergic contact dermatitis, and lichen planus is corticosteroids. Pruritus, a common sign of autoimmune and inflammatory skin conditions, can be extremely uncomfortable and negatively affect a patient's quality of life. Moisturizers, emollients, and barrier repair creams usually lessen pruritus by enhancing barrier function.
Leading market players are significantly investing in research and development to create innovative pruritus therapies. Investments are also being made to advance existing therapeutics. In addition, launching new medications and building a strong product pipeline is the major focus of key players. Moreover, owing to their low cost and convenience of availability, over-the-counter topical medicines are in high demand. As a result, patients are turning more frequently to over-the-counter treatments. These drivers provide a favorable environment for increasing sales of pruritus products and for growth of the overall market. However, lack of knowledge regarding cause of the disease creates hindrance to the market. Moreover, patent expiry of various pruritus therapeutic products provide a greater opportunity for market players to grow their business.
The pruritus therapeutics market is segmented on the basis of drug type, disease, distribution channel, and region. On the basis of drug type, the market is segmented into corticosteroids, antihistamines, local anesthetics, immunosuppressants, and others. On the basis of disease type, it is segmented into atopic dermatitis, allergic contact dermatitis, urticaria, and others. On the basis of distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment is further segmented on the basis of route of administration into oral route, parenteral route, and topical route. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Major companies profiled in this report include AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Cara therapeutics, Inc., Cipla Ltd., Eilly Lilly and Company, Evelo Bioscience, Galderma S.A., LEO Pharma, MC2 Therapeuitics, Novan Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Trevi therapeutics and Viatris Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pruritus therapeutics market analysis from 2021 to 2031 to identify the prevailing pruritus therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pruritus therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pruritus therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug type
Corticosteroids
Antihistamines
Local Anesthetics
Immunosuppressant
Others
By Disease Type
Atopic Dermatitis
Allergic Contact Dermatitis
Urticaria
Others
By Distribution Channel
Hospital Pharmacies
Drug stores Retail Pharmacies
Route of Administration
Oral
Parenteral
Topical
Online providers
By Region
North America
U.S.
Canada
Mexico
Europe
France
UK
Italy
Spain
Rest of Europe
Germany
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
AbbVie Inc.
Amgen Inc.
Bausch Health Companies Inc.
Cara therapeutics, Inc.
Cipla Ltd.
Eilly Lilly and company
Evelo Biosciences
Galderma S.A.
LEO Pharma
MC2 therapeuitics
Novan, Inc
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc
Sanofi
Trevi therapeutics
Viatris Inc. (Mylan NV)
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook